India’s Risk-Based Inspection Plan: Well Begun?
This article was originally published in PharmAsia News
India's CDSCO is taking definitive steps to strengthen the regulatory regime and enforcement, including across areas such as data integrity, against the backdrop of industry's patchy manufacturing compliance.
You may also be interested in...
India has outlined key aspects of its recently introduced perpetual licensing system, including initial modalities around joint inspections of manufacturing units by central and state drug inspectors.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.